ANALYSIS: Like many other medicinal cannabis companies, Greenfern is about to attempt raising more capital but some offers may be better than others.
ANALYSIS: It’s likely NZGCP’s Elevate fund-of-funds will miss out on a second vintage in this week’s Budget 2024. How will that affect VCs struggling to raise new funds?
ANALYSIS: Mistaken information, deep fakes, and deceitful, orchestrated campaigns have destroyed trust in governments and media – but business can also be its target.
ANALYSIS: A 2011 plan to become an international funds domicile hasn’t come to fruition, but it may still have legs.
ANALYSIS: Many believe the global south is on the rise. Should America’s enemies be ours too?
ANALYSIS: Medicinal cannabis has been legal since 2016 and while more than one million Australians have been prescribed cannabis products, the industry continues to struggle for profitability.
ANALYSIS: Innovation agency’s role and function is under review by the govt-appointed panel making recommendations on NZ’s science, innovation and technology system.
ANALYSIS: NZ Post’s robust defence of a model it knows has flaws has sobering echoes of the UK Post Office scandal.
ANALYSIS: Wine powerhouse Indevin’s pursuit of scale through cloud computing provides an exemplar for Kiwi horticulture.
ANALYSIS: Former VC investor Andrew Chen drew more than 100 comments on a controversial article ‘New Zealand startup valuations are too low. We should fix that’. Shoeshine identifies 10 fixes that could help.